Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Completed
Amgen
Phase 2
2005-01-01
The purpose of this study is to determine if palifermin will reduce the incidence of
dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation
chemotherapy for treatment of unresectable stage III Non-Small Cell Lung Cancer (NSCLC).
Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Completed
Swedish Orphan Biovitrum
Phase 2
2005-01-01
The purpose of this study is to determine if palifermin will reduce the incidence of
dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation
chemotherapy for treatment of unresectable stage III Non-Small Cell Lung Cancer (NSCLC).
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Completed
Amgen
Phase 3
2005-08-01
The purpose of this research study is to test the safety and effectiveness of palifermin to
determine if weekly doses can be safely administered to reduce the incidence (occurrence of),
duration (length of time) and severity (amount of pain) of oral mucositis (painful sores in
the mouth). Mucositis is a common side effect for patients receiving chemotherapy
(cancer-killing drug) and radiotherapy (cancer-killing x-rays) for the treatment of head and
neck cancer (HNC).
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Completed
Swedish Orphan Biovitrum
Phase 3
2005-08-01
The purpose of this research study is to test the safety and effectiveness of palifermin to
determine if weekly doses can be safely administered to reduce the incidence (occurrence of),
duration (length of time) and severity (amount of pain) of oral mucositis (painful sores in
the mouth). Mucositis is a common side effect for patients receiving chemotherapy
(cancer-killing drug) and radiotherapy (cancer-killing x-rays) for the treatment of head and
neck cancer (HNC).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
